MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens
Authors:
Open Access
- 9 May 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Abstract
O6-methylguanine-DNA methyltransferase (MGMT) has been linked with alkylating agent resistance and tumor growth suppression. However, its role remains undetermined in pancreatic neuroendocrine tumors (Pan-NET). The MGMT expression was examined by immunohistochemistry in 142 patients to evaluate MGMT immunoreactivity and clinicopathological factors. We analyzed the relationship between MGMT expression and treatment efficacy in 19 patients who received STZ-based regimens. In 142 Pan-NET, 97 cases (68.3%) were judged as MGMT-positive and 45 cases (31.6%) as negative. MGMT negativity was significantly more common in NET-G2 (62.5%) than in NET-G1 (11.2%, p < 0.001). MGMT-negative cases were associated significantly with larger tumor size (p < 0.01), higher Ki-67 index (p < 0.01), higher mitotic index (p < 0.05), and more frequent liver metastasis (p < 0.05). Of the 19 cases treated with STZ, 6 cases were determined as SD and 4 cases as PD in MGMT-positive patients (N = 10), while 5 cases were determined as PR and 4 cases as SD in MGMT-negative patients (N = 9). Progression-free survival in MGMT-negative cases was significantly better than in MGMT-positive cases (p < 0.05). MGMT expression was lower in NET-G2 than in NET-G1, and STZ-based regimens improved the therapeutic outcomes of MGMT-negative Pan-NET. These findings indicate that NET-G2 may represent a better therapeutic target for STZ treatment.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Correlation of MLH1 and MGMTexpression and promoter methylation with genomic instability in patients with thyroid carcinomaBMC Cancer, 2013
- MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistryJournal of Cancer Research and Clinical Oncology, 2012
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialThe Lancet Oncology, 2012
- DNA Methylation Profiles of Primary Colorectal Carcinoma and Matched Liver MetastasisPLOS ONE, 2011
- Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutationsCell Cycle, 2011
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumorsEndocrine-Related Cancer, 2008
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 2007